Galapagos Priced, Nasdaq: GLPG

Belgian biotech developing new treatments for inflammatory diseases.

Industry: Health Care

Latest Trade: $82.37 0.00 (0.0%)

First Day Return: +20.1%

Return from IPO: +95.9%

Industry: Health Care

Galapagos is a clinical-stage biotechnology company specialized in the discovery and development of small molecule medicines with novel modes of action, addressing disease areas of high unmet medical need. Execution on our proprietary drug target discovery platform has delivered a pipeline of three Phase 2 programs, two Phase 1 trials, five pre-clinical studies, and 20 discovery small-molecule and antibody programs. While our highly flexible platform offers applicability across a broad set of therapeutic areas, our most advanced clinical candidates are in inflammatory related diseases: rheumatoid arthritis; inflammatory bowel disease; cystic fibrosis; and pulmonary disease, including idiopathic pulmonary fibrosis. Our lead programs include GLPG0634, or filgotinib, in three Phase 2b trials for RA (DARWIN trials) and one Phase 2 trial for Crohn’s disease (FITZROY trial); GLPG1205 in a Phase 2a trial for ulcerative colitis (ORIGIN trial); GLPG1690, for which we expect to conduct a Phase 2a trial for IPF; and a series of novel potentiators and correctors for CF in Phase 1 and in pre-clinical stages. Almost exclusively, these programs are derived from our proprietary target discovery platform and, we believe, represent potential best-in-class treatments.
more less
IPO News for Galapagos
more
IPO Data
IPO File Date 04/15/2015
Offer Price $42.05
Price Range $41.52 - $41.52
Offer Shares (mm) 6.6
Deal Size ($mm) $275
IPO Data
IPO Date 05/13/2015
Offer Price $42.05
Price Range $41.52 - $41.52
Offer Shares (mm) 6.6
Deal Size ($mm) $275
Underwriters
more
Company Data
Headquarters Mechelen, Belgium
Founded 1999
Employees 417
Website www.glpg.com